

Joe Lombardo
Governor

Richard Whitley, MS
Director



**DEPARTMENT OF
HEALTH AND HUMAN SERVICES**
DIVISION OF HEALTH CARE FINANCING AND POLICY
Helping people. It's who we are and what we do.



Stacie Weeks,
JD MPH
Administrator

Drug Utilization Review

Board Meeting Minutes

Date of Meeting: Thursday, January 19, 2023

Name of Organization: The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP),
Drug Use Review Board

Agenda Item	Record	Notes																														
1. Call to Order and Roll Call	<p>It was announced the meeting is being recorded.</p> <p>Chairperson Wheeler called the meeting to order at 1:12 p.m. on January 19, 2023.</p> <p>Chairperson Wheeler took the roll.</p> <table><thead><tr><th></th><th>Present</th><th>Absent</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Present	Absent	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<p>DHCFP Staff Present were as follows:</p> <ul style="list-style-type: none">• Griffin, Karen, Senior Deputy Attorney General (SDAG)• Olsen, David, Chief of Pharmacy Services• Gudino, Antonio, Manager of Pharmacy Services• Clemons, Roshanda, Medical Director• Berntson, Kindra, Social Services Program Specialist II (SSPS II), Pharmacy Unit• Flowers, Ellen, Program Officer I, Pharmacy Unit <p>Magellan Rx Staff Present were as follows:</p> <ul style="list-style-type: none">• Mishra, Raj, Pharm.D., Clinical Account Manager• Kim, James, Pharm.D., Dir. Clinical Account Services
	Present	Absent																														
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Mark Canty, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
• Crystal Castaneda, MD	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input checked="" type="checkbox"/>																														
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>																														

		<ul style="list-style-type: none"> • Martinez, Chris, Sr. Business Analyst • Chow, Connie, Pharm.D., Clinical Account Manager • Killpack, Andy, Pharm.D., Dir. Specialty Clinical Solutions <p>Managed Care Organization representatives present were as follows:</p> <ul style="list-style-type: none"> • Lim, Luke, Pharm.D., Anthem • Bitton, Ryan, Pharm.D., Health Plan of Nevada • Miro, Trashelle, Pharm.D., Silver Summit Health Plan • Tran, Jimmy, Pharm.D., Molina Healthcare <p>The public attendee list is included as Attachment A.</p> <p>Note: Participants may not have chosen to reveal their identity, and in the absence of a sign-in sheet, the attendee list's accuracy is not assured.</p>
2. General Public Comment	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
3. Administrative		
<p>a. For Possible Action: Review and Approve Meeting Minutes from October 20 , 2022</p>	<p>Board Member Netochi moved to approve the minutes as presented, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

	<div> <div>Yes</div> <div>No</div> <div>Abst.</div> </div> <ul style="list-style-type: none"> • Jennifer Wheeler, Pharm.D., Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Netochi Adeolokun, Pharm.D., Vice Chair <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Mark Canty, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Crystal Castaneda, MD <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jessica Cate, Pharm.D. <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
b. Status Update by DHCFP	<p>Chief of Pharmacy Services David Olsen provided five announcements.</p> <ul style="list-style-type: none"> • The division would like to welcome Doctor Roshanda Clemons as the new Medicaid Medical Director. • The division would also like to thank and recognize Doctor Michael Owens. He recently resigned his board position with the Drug Utilization Review Board. We are also accepting resumes and CVs from health providers for board members for both boards the Drug Utilization Review Board and Silver State Scripts Board. If there's interest, you can e-mail pharmacy services at RXinfo@dhcfp.nv.gov. • Nevada Medicaid has established licensed pharmacists as a new provider type. Services related to dispensing self-administered contraceptives and prescribing HIV prevention medications are now reimbursable when provided by a pharmacist enrolled Nevada Medicaid provider. For more information on how to enroll as a Nevada Medicaid provider, please visit the provider enrollment page that's found at the website www.medicaid.nv.gov. Nevada Medicaid is working on a project to manage provider administered drugs. Prior authorizations will be required for a list of 60 specialty drugs. It is tentatively scheduled to implement as 	

	soon as April 24 th , 2023, and subject to change. This project is specific to only fee-for-service.	
4. Clinical Presentations		
a. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for NUCALA and DUPIXENT.		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No public comment was provided.	
ii. Presentation of utilization and clinical information.	Dr. Raj Mishra provided the clinical background and indications for NUCALA and DUPIXENT. Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of Nucala and Dupixent. <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. • Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.	
iv. Proposed adoption of updated prior authorization criteria.	Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Adeolokun seconded the motion. A vote was taken, and the results were as follows from members in	

	<div>attendance (in favor, against, and abstentions where applicable):</div> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
b. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for PENICILLAMINE.																																										
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<div>Telephonic and web comment was called for, and the phone lines were opened.</div> <div>No public comment was provided.</div>																																									
ii. Presentation of utilization and clinical information.	<div>Dr. Mishra provided the clinical background and indications for PENICILLAMINE.</div> <div>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for Penicillamine.</div> <div><ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.</div>																																									

	<ul style="list-style-type: none">Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Le moved to approve the criteria as presented by Magellan, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
c. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for RAYALDEE (CALCIFEDIOL).																																										
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened.																																									

	No public comment was provided.																													
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra provided the clinical background and indications for RAYALDEE (CALCIFEDIOL).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization for RAYALDEE (CALCIFEDIOL).</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented with the recommendation of adding the following criteria. Dose does not exceed 60 MCG (2capsules) per day. <p>Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</p>																													
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																													
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																											
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																											
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																											

	<ul style="list-style-type: none"> Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
d. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for RELYVRIO (SODIUM PHENYLBUTYRATE/TAURURSODIOL).		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Mishra discussed the new drug update and provided clinical background for RELYVRIO (SODIUM PHENYLBUTYRATE/TAURURSODIOL).</p> <p>Dr. Mishra reviewed the proposed criteria presented in the binder and discussed the utilization of RELYVRIO (SODIUM PHENYLBUTYRATE/TAURURSODIOL)</p> <ul style="list-style-type: none"> Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented. 	

iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Trans seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table> <thead> <tr> <th></th><th>Yes</th><th>No</th><th>Abst.</th></tr> </thead> <tbody> <tr> <td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> <tr> <td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr> <tr> <td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr> </tbody> </table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
e.	For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for PEGFILGRASTIM.																																										
i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Ben Droese pharmacist with Amgen medical affairs provided a public comment.</p>																																									

ii.	Presentation of utilization and clinical information.	<p>Dr. Killpack provided the clinical background and indications for PEGFILGRASTIM.</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of PEGFILGRASTIM.</p> <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. <p>Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</p>																																									
iii.	Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>																																									
iv.	Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member Adeolokun seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																								
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																								

f. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for ARANESP (DARBEPOETIN ALFA).		
i. <u>Public comment</u> on proposed clinical prior authorization criteria.	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>No public comment was provided.</p>	
ii. Presentation of utilization and clinical information.	<p>Dr. Killpack provided the clinical background and indications for ARANESP (DARBEPOETIN ALFA)</p> <p>Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization for ARANESP (DARBEPOETIN ALFA).</p> <ul style="list-style-type: none"> • Dr. Lim with Anthem, approved of the proposed criteria and utilization presented. • Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented. • Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. <p>Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.</p>	
iii. Discussion by Board and review of utilization data.	<p>Chairperson Wheeler asked for comments from the Board Members.</p> <p>No comments were made.</p>	
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Le moved to approve the criteria as presented by Magellan, and Board Member Tran seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p>	

	<div><div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></div><div><div><div></div><div></div><div></div></div><div><div><div></div><div></div><div></div></div></</div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div></div>
--	---

	<ul style="list-style-type: none">• Dr. Miro with Silver Summit Health Plan, approved of the proposed criteria and utilization presented.• Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																																									
iii. Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																																									
iv. Proposed adoption of updated prior authorization criteria.	<p>Board Member Tran moved to approve the criteria as presented by Magellan, and Board Member England seconded the motion.</p> <p>A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable):</p> <table><thead><tr><th></th><th>Yes</th><th>No</th><th>Abst.</th></tr></thead><tbody><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Dave England, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Brain Le, DO</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Rebecca Sparks, PA-C</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jim Tran, Pharm.D.</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr></tbody></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	
	Yes	No	Abst.																																							
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Dave England, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Brain Le, DO	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
• Rebecca Sparks, PA-C	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																																							
• Jim Tran, Pharm.D.	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																																							
h. For Possible Action: Discussion and possible adoption of prior authorization criteria and/or quantity limits for OCREVUS (OCRELIZUMAB).																																										

i.	<u>Public comment</u> on proposed clinical prior authorization criteria.	Telephonic and web comment was called for, and the phone lines were opened. No Public comment was provided.																									
ii.	Presentation of utilization and clinical information.	Dr. Killpack discussed the indication for the new drug update for OCREVUS (OCRELIZUMAB). Dr. Killpack reviewed the proposed criteria presented in the binder and discussed the utilization of OCREVUS (OCRELIZUMAB). <ul style="list-style-type: none">• Dr. Lim with Anthem, approved of the proposed criteria and utilization presented.• Dr. Bitton with Health Plan of Nevada, approved of the proposed criteria and utilization presented.• Dr. Beranek with Silver Summit Health Plan, approved of the proposed criteria and utilization presented. Dr. Tran with Molina Healthcare, approved of the proposed criteria and utilization presented.																									
iii.	Discussion by Board and review of utilization data.	Chairperson Wheeler asked for comments from the Board Members. No comments were made.																									
iv.	Proposed adoption of updated prior authorization criteria.	Board Member Adeolokun moved to approve the criteria as presented by Magellan, and Board Member Le seconded the motion. A vote was taken, and the results were as follows from members in attendance (in favor, against, and abstentions where applicable): <table><tr><td></td><td>Yes</td><td>No</td><td>Abst.</td></tr><tr><td>• Jennifer Wheeler, Pharm.D., Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Netochi Adeolokun, Pharm.D., Vice Chair</td><td><input checked="" type="checkbox"/></td><td><input type="checkbox"/></td><td><input type="checkbox"/></td></tr><tr><td>• Mark Canty, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Crystal Castaneda, MD</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr><tr><td>• Jessica Cate, Pharm.D.</td><td><input type="checkbox"/></td><td><input type="checkbox"/></td><td><input checked="" type="checkbox"/></td></tr></table>		Yes	No	Abst.	• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>	
	Yes	No	Abst.																								
• Jennifer Wheeler, Pharm.D., Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																								
• Netochi Adeolokun, Pharm.D., Vice Chair	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>																								
• Mark Canty, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Crystal Castaneda, MD	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								
• Jessica Cate, Pharm.D.	<input type="checkbox"/>	<input type="checkbox"/>	<input checked="" type="checkbox"/>																								

	<ul style="list-style-type: none"> • Dave England, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Brain Le, DO <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> • Rebecca Sparks, PA-C <input type="checkbox"/> <input type="checkbox"/> <input checked="" type="checkbox"/> • Jim Tran, Pharm.D. <input checked="" type="checkbox"/> <input type="checkbox"/> <input type="checkbox"/> 	
5. DUR Board Requested Reports		
a. Opioid Reports: <ul style="list-style-type: none"> i. Opioid Trends ii. Count of Claims iii. Med Trend iv. Top Members v. Top Ten Prescribers vi. MED 	<ul style="list-style-type: none"> • Dr. Mishra presented opioid utilization reports. • Dr. Lim presented opioid utilization reports. • Dr. Bitton presented opioid utilization reports. • Dr. Miro presented opioid utilization reports. • Dr. Tran presented opioid utilization reports. 	
b. Standard DUR Reports: <ul style="list-style-type: none"> i. Top 10 Classes by amount paid ii. By Claim Count iii. cDUR Quarterly Report iv. cDUR Detail Activity Summary v. cDUR Detailed Saving Outcome vi. Retro DUR 	<ul style="list-style-type: none"> • Dr. Mishra presented Standard DUR Reports • Dr. Lim presented Standard DUR Reports. • Dr. Bitton presented Standard DUR Reports • Dr. Miro presented Standard DUR Reports • Dr. Tran presented Standard DUR Reports. 	
6. Closing Discussion		
a. Public Comment	<p>Telephonic and web comment was called for, and the phone lines were opened.</p> <p>Public comment was provided by Amy Hale Principal Scientific account with Scientific Affairs and pharmacist in Nevada for Ketamine or Spravato.</p>	
b. For Possible Action: Date and location of the next meeting.	<p>Chairperson Wheeler stated the next meeting is scheduled for April 20, 2023.</p> <p>Location: Hilton Garden Inn Reno</p>	

c. Adjournment	The meeting adjourned at 2:38 p.m.	
----------------	------------------------------------	--

Attachment A – Members of the Public in Attendance

Budsberg, Scott	Yip, Brandon /US	Cheryl Donahue	Karen Ou
Joe Germain Jr.	Lea Case	Craig Irwin	Roa, Ryan A
Crecco, Jason	Harrison, Emily	Sommers, Melissa	Warner Quon
Gary Parenteau	Droese, Ben	Michael Zarob	Chris G
Nicholas Boyer	GNH (Gina Heinen)	Colabianchi, Jeana	Deb Guay
Michael Pazirandeh	Susan Hertzberg	Todd Dickerson	
Gittinger William	Wright, Kelly	Zimmer, Eileen	
Joe Gelinas	Kelvin Yamashita	John E Davis	
Mike Turk	Mark Germann	Monz, Dana	
Pulver, Lisa [JANUS]	Valerie D Ng	Christina Hartmann	

Attachment B – Submitted Written Comment

No written comments submitted